Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Portfolio Pulse from
Volition has announced the enrollment of the first patient in NTU Hospital's study to validate the Nu.Q® Lung Cancer Test, which differentiates between malignant and benign nodules. The study is expected to conclude by the end of 2025.
March 11, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Volition has initiated a study at NTU Hospital to validate its Nu.Q® Lung Cancer Test, which can differentiate between malignant and benign nodules. This development could enhance the test's credibility and market potential.
The initiation of a validation study for the Nu.Q® Lung Cancer Test is a significant step for Volition, as it could lead to increased adoption and credibility of the test. Successful results could positively impact VNRX's stock by enhancing its product portfolio and market reach.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90